A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Study Summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Conditions

Solid Tumors Advanced Solid Tumors Metastatic Solid Tumors

Interventions / Drugs

INCA33890 bevacizumab FOLFIRI FOLFOX Cetuximab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment408 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647719+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.